 |
|
|
| |
Impact of Elbasvir/Grazoprevir (EBR/GZR) on Health-Related Quality of Life (HRQOL) and Fatigue in Patients With Chronic Hepatitis C Virus (HCV) Infection and Inherited Blood Disorders (IBLD): Data From the C-EDGE IBLD Study
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
John M. Vierling*1; Abhasnee Sobhonslidsuk2; George Papatheodoridis3; Nimer Assy4; William Rosenberg5; Dominque Guyader6; Anouk Dev7; Stuart C. Gordon8; Stanislas Pol9; Velimir A. Luketic10; Saro Khemichian11; Barbara Evans12; Leslie Morgan12; Meng Li12; Rohit Talwani12; Jean Marie Arduino12; Paul Kwo13
1Baylor College of Medicine, Houston, TX, USA; 2Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 3Laiko General Hospital, National and Kapodistroan University of Athens, Greece; 4Galilee Medical Center, Western Galilee, Israel; 5Institute for Liver and Digestive Health UCL, London, United Kingdom; 6Hopital Pontchaillou, Rennes, France; 7Monash Health, Melbourne, Australia; 8Henry Ford Health System, Detroit, MI, USA; 9Hopital Cochin, Paris, France; 10McGuire Research Institute and Virginia Commonwealth University School of Medicine, Richmond, VA, USA; 11Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; 12Merck & Co., Inc., Kenilworth, NJ, USA; 13Stanford University Medical Center, Stanford, CA, USA
|
| |
|
|
|
|
|
